Bull Horn Holdings (BHSE) Shareholders Approve Coeptis Therapeutics Deal

Bull Horn Holdings Corp. (NASDAQ:BHSE) disclosed this afternoon that its shareholders have approved its combination with biopharmaceutical company Coeptis (OTC:COEP) in a special meeting held earlier today.

A total of 2,869,654 ordinary shares, or approximately 88.5% of Bull Horn’s outstanding public shares, were redeemed at today’s meeting. But, the SPAC had already faced previous redemptions of 4,258,586 public shares during a shareholder vote for a timeline extension back in April. This brings the total amount redeemed to 95.04% following today’s completion vote. As a result, BHSE will have approximately 371,760 public shares and $3.8 million remaining in its trust account following the redemptions.

Despite the high amount of redemptions, Bull Horn still expects the deal to be completed promptly following the satisfaction or waiver of the other conditions to the consummation of the business combination. The combined company is expected to trade under the symbol “COEP” once the deal is completed.

The parties initially announced their business combination on April 19. Wexford, Pennsylvania-based Coeptis is developing a pair of therapies designed to improve the efficacy of cancer treatments.

ADVISORS

• Bridgeway Capital Partners served as financial advisors to Coeptis.
• Meister Seelig & Fein LLP served as legal advisors to Coeptis.
• Jones Trading served as financial advisor to Bull Horn.
• Ellenoff Grossman & Schole LLP served as legal advisors to Bull Horn.